Sunshine Biopharma Inc. - Common stock (SBFM)
Frequently Asked Questions About Sunshine Biopharma Inc. - Common stock (SBFM)
Does Sunshine Biopharma have any partnerships?
Sunshine Biopharma actively seeks partnerships with other biotechnology and pharmaceutical companies to enhance its research capabilities and expedite product development. Collaborations may include joint ventures, licensing agreements, and research collaborations aimed at leveraging shared expertise and resources.
How can potential investors learn more about Sunshine Biopharma?
Potential investors can learn more about Sunshine Biopharma by visiting the company's official website, reviewing their latest annual reports, and following press releases and news updates. The company also participates in investor conferences where executives provide insights into its strategies and growth prospects.
How does Sunshine Biopharma communicate with investors?
Sunshine Biopharma maintains open lines of communication with investors through regular press releases, quarterly earnings reports, and corporate presentations. The company's management is committed to transparency and actively engages with shareholders to keep them informed about progress and milestones.
How does Sunshine Biopharma contribute to the community?
Sunshine Biopharma is committed to contributing to the community through various initiatives, including collaborations with research institutions and participation in public health awareness campaigns. The company also focuses on ethical practices in drug development and strives to improve patient health outcomes in the populations it serves.
How does Sunshine Biopharma ensure the safety of its drugs?
Safety is a top priority for Sunshine Biopharma. The company adheres to stringent regulatory requirements throughout the drug development process, conducting thorough preclinical and clinical studies to assess the safety, dosing, and efficacy of its drug candidates before they reach the market.
Is Sunshine Biopharma Inc. publicly traded?
Yes, Sunshine Biopharma Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol SBFM. This listing allows the company to raise capital for its research and development efforts and provides investors with an opportunity to participate in the growth of the biotechnology sector.
What are some products in Sunshine Biopharma's pipeline?
Sunshine Biopharma's pipeline includes several promising drug candidates aimed at various types of cancer. Notable candidates include its lead drug, SBFM-101, which targets specific cancer cells while minimizing damage to healthy tissues, highlighting the company's commitment to effective and targeted cancer therapies.
What are the company's financials like?
Sunshine Biopharma's financials reflect its focus on research and development expenditures typical for biotech companies. While the company may not yet be profitable, it seeks to achieve growth through strategic funding initiatives, including public offerings and investment from venture capital.
What challenges does Sunshine Biopharma face?
Like many biotech firms, Sunshine Biopharma faces challenges such as navigating complex regulatory pathways, ensuring adequate funding for research and development, and competing against larger pharmaceutical companies. Additionally, the company must continually innovate to advance its drug pipeline and meet market demands.
What does Sunshine Biopharma Inc. do?
Sunshine Biopharma Inc. is a biotechnology company focused on the development of drugs for the treatment of cancer and other serious diseases. The company primarily seeks to address unmet medical needs in oncology with its innovative drug candidates, leveraging advanced technologies and scientific research.
What is SBFM-101?
SBFM-101 is one of the lead drug candidates developed by Sunshine Biopharma, which is designed to treat various forms of cancer. The drug operates on the principle of selectively targeting cancer cells, showing promise in preclinical studies for its efficacy and reduced side effects compared to conventional therapies.
What is the company's approach to drug development?
Sunshine Biopharma employs a rigorous approach to drug development, focusing on scientific research and leveraging advanced technologies. The company prioritizes the identification of molecular targets and conducts extensive preclinical and clinical testing to ensure the safety and effectiveness of its drug candidates.
What is the competitive landscape for Sunshine Biopharma?
Sunshine Biopharma operates in a highly competitive landscape dominated by other biotech and pharmaceutical companies developing cancer treatments. To differentiate itself, Sunshine Biopharma focuses on niche markets and targets specific cancer types, leveraging its unique drug candidates and proprietary technology.
What is the significance of the Nasdaq listing for Sunshine Biopharma?
The Nasdaq listing provides Sunshine Biopharma with increased visibility and credibility in the financial markets. It allows the company to access a broader investor base and facilitates the raising of capital, essential for funding its ongoing research and development efforts.
What is the vision and mission of Sunshine Biopharma Inc.?
The mission of Sunshine Biopharma is to discover and develop innovative medicinal therapies aimed at improving patient outcomes, particularly in the field of oncology. The company's vision is to become a leader in the biopharmaceutical industry by addressing significant healthcare challenges through groundbreaking research and development.
What markets does Sunshine Biopharma target?
Sunshine Biopharma targets the global oncology market, which encompasses a wide range of cancers including breast, lung, and prostate cancer. The company aims to address the growing demand for effective and innovative cancer treatments while expanding its reach into other therapeutic areas over time.
What regulatory approvals has Sunshine Biopharma received?
As of now, Sunshine Biopharma has submitted applications for various regulatory approvals, including Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for its lead products. The company is actively working towards progressing through the necessary phases of clinical trials to obtain market authorization.
When was Sunshine Biopharma Inc. founded?
Sunshine Biopharma Inc. was founded in 2006. Since its inception, the company has focused on developing novel therapies and expanding its product pipeline to address critical health challenges.
Where is Sunshine Biopharma Inc. headquartered?
Sunshine Biopharma Inc. is headquartered in Montreal, Canada. The location provides the company with access to a robust network of biotech and pharmaceutical resources, as well as a skilled workforce in the life sciences sector.
Who are the key executives at Sunshine Biopharma Inc.?
Sunshine Biopharma's leadership team includes experienced professionals from the biotechnology and pharmaceutical industries. The team is led by Dr. Steve N. Slilaty, the CEO, who brings extensive knowledge in drug development and corporate management, along with a dedicated team of scientists and business experts.
What is the current price of Sunshine Biopharma Inc. - Common stock?
The current price of Sunshine Biopharma Inc. - Common stock is 1.610
When was Sunshine Biopharma Inc. - Common stock last traded?
The last trade of Sunshine Biopharma Inc. - Common stock was at 2:55 pm EDT on April 4th, 2025